23 Oct

What Analysts Recommend for Eli Lilly

WRITTEN BY Mike Benson

Wall Street analysts’ estimates

Eli Lilly (LLY) surpassed Wall Street analyst estimates for revenues and reported revenues of $5.8 billion for 2Q17 as compared to the estimates of $5.6 billion. The company also surpassed analysts’ estimates for EPS (or earnings per share) and reported EPS of $1.11 per share against EPS estimates of $1.05. Analysts estimate EPS of $1.03 on revenues of $5.52 billion for 3Q17.

What Analysts Recommend for Eli Lilly

The above chart shows changes in analysts’ recommendations for Eli Lilly over the last 12 months.

Analyst ratings

Eli Lilly stock has returned nearly 10.8% in the last 12 months and nearly 18.6% in 2017 year-to-date. Analysts estimate the stock will rise 4.3% over the next 12 months. Wall Street analysts gave a 12-month target price of $90.95 per share as compared to the last price of $87.23 per share as of October 20, 2017.

As of October 23, 2017, there are 22 analysts tracking Eli Lilly. Of these, 13 analysts recommend a “buy,” while eight analysts have recommended a “hold,” and one analyst recommends a “sell.” The consensus rating for Eli Lilly stands at 2.27, which represents a moderate buy for long-term growth investors and value investors. The changes in analysts’ estimates and recommendations are based on the changing trends in the stock price and performance of the company.

The Vanguard Healthcare ETF (VHT) holds 2.3% of its assets in Eli Lilly (LLY). VHT also holds 2.7% in Bristol-Myers Squibb (BMY), 5.5% in Pfizer (PFE), and 5.0% in Merck (MRK).

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

14 Jun

Why Kimberly-Clark Stock May Stop Rising

WRITTEN BY Amit Singh

Kimberly-Clark (KMB) stock has risen 20.5% this year, boosted by the company’s better-than-expected sales and earnings during its last reported quarter. However, its stock could stop climbing. Here's why.

172.31.59.107